Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial

Jordana B. CohenThomas C. HanffPreethi WilliamNancy K. SweitzerNelson R. Rosado‐SantanderC. MedinaJuan E. Rodriguez‐MoriNicolás RennaTara I. ChangVicente Corrales‐Medina2026-03-222026-03-22202110.1016/s2213-2600(20)30558-0https://doi.org/10.1016/s2213-2600(20)30558-0https://andeanlibrary.org/handle/123456789/43130Citaciones: 223enDiscontinuationMedicineCoronavirus disease 2019 (COVID-19)Renin–angiotensin systemOpen label2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Prospective cohort studyClinical trialInternal medicineContinuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trialarticle